Adm Tronics Stock Price, News & Analysis

ADM Tronics Unlimited, Inc. (OTCQB: ADMT) reported its third fiscal quarter results for FY 2023, highlighting a net income of $155,148 for the nine months ended December 31, 2022, a turnaround from a net loss of $140,221 a year prior. Revenues surged over 31% to $3,044,838 compared to $2,322,871 for the same period in 2021. The Electronics segment alone saw a revenue increase of over 73%. For the latest quarter, ADMT also posted a net income of $93,771, contrasting a net loss of $72,393 for the same quarter last year. The company attributes its revenue growth to all three operational segments: Electronics, Engineering, and Chemical.

ADM Tronics Unlimited (OTCQB: ADMT) reported a 27% increase in revenues for Q1 FY2023, totaling $921,408 compared to $721,358 in the prior year. Despite facing challenges from supply chain issues and increased raw material costs, the company maintained a 42% gross profit margin. R&D expenses decreased by 23%, reflecting the nearing completion of the Vet-Sonotron technology development. Loss from operations also improved, decreasing by 20% to $34,625. ADMT anticipates continued revenue growth.

ADM Tronics Unlimited, Inc. (OTCQB:ADMT) announced fiscal results for the year ending March 31, 2022, showing revenues of $3.21 million, a 4% increase from the prior year. Gross profit rose to $1.25 million, approximately 39% of revenues. Operating expenses increased to $2.38 million, leading to a net loss of $1.38 million. The company remains focused on the commercialization of its Vet-Sonotron technology despite ongoing supply chain issues. Positive future growth opportunities are anticipated from both Vet-Sonotron and the upcoming Sonotron Mark 2.

Aveta Life is collaborating with ADM Tronics Unlimited (OTCQB - ADMT) to develop the Hormonometer™, a new hormonal diagnostic platform. This innovative technology aims to enhance women's health through at-home hormonal monitoring. ADMT will provide regulatory guidance for the product to meet US FDA and CE certifications. CEO Andre’ DiMino will join Aveta Life's Advisory Board, contributing extensive experience in medical device development. The collaboration signals a significant step toward advancing women's health technology and ensuring compliance with regulatory standards.

ADM Tronics Unlimited, Inc. (OTCQB: ADMT) reported mixed results for its third fiscal quarter ending December 31, 2021. Revenue decreased by $12,990 to $749,654 due to declines in the Chemical and Engineering segments, despite an increase in Electronics. However, year-to-date revenue rose by $64,049. Gross profit improved by $46,657, supported by enhanced performance in Engineering and Chemical sectors. Operational expenses surged, leading to a loss of $416,172 for the quarter. Significant increases in other income resulted from the forgiveness of the PPP Loan totaling $332,542.

ADMT announced positive results from a study by North Carolina State University on its Calmer Canine device, effective in treating canine separation anxiety (CSA). The double-blind, placebo-controlled study showed that two-thirds of treated dogs had a 100% improvement in resting behavior after four weeks. Approximately 13 million dogs in the US suffer from CSA, highlighting the potential market impact of this non-invasive therapy. Calmer Canine is manufactured at ADMT's facility in NJ, signaling strong manufacturing capabilities and market readiness.

ADM Tronics Unlimited, Inc. (OTCQB: ADMT) announced its financial results for the second fiscal quarter ended September 30, 2021. Revenues totaled $851,859, an 8% decrease from the previous year, primarily due to supply chain challenges impacting their electronics and chemical segments. However, revenues for the first six months increased by 5% to $1,573,217. The company reported a loss from operations of $552,574, significantly down from a profit of $5,366 last year, impacted by non-cash expenses and increased allowances for doubtful accounts.